N
NIAGEN BIOSCIENCE, INC.
NASDAQ: NAGE (Niagen Bioscience, Inc.)
Last update: 2 hours ago3.11
-0.06 (-1.89%)
| Previous Close | 3.17 |
| Volume | 242,245 |
| Price / Earnings (Forward) | 22.94 |
| Price / Sales | 2.11 |
| Price / Book | 3.08 |
| 52 Weeks Range |
| Profit Margin | 13.07% |
| Operating Margin (TTM) | 15.66% |
| Diluted EPS (TTM) | 0.180 |
| Quarterly Revenue Growth (YOY) | 37.60% |
| Quarterly Earnings Growth (YOY) | 6,197.40% |
| Total Debt/Equity (MRQ) | 6.37% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 19.70 M |
| Levered Free Cash Flow (TTM) | 15.43 M |
| Return on Assets (TTM) | 12.21% |
| Return on Equity (TTM) | 33.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Niagen Bioscience, Inc. | Mixed | Bearish |
AIStockmoo Score
1.5
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.50 |
|
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 34.44% |
| % Held by Institutions | 33.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Steelpeak Wealth, Llc | 30 Jun 2026 | 3,500,129 |
| Tieton Capital Management, Llc | 30 Jun 2026 | 2,008,470 |
| Qube Research & Technologies Ltd | 30 Jun 2026 | 1,625,016 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |